Lepodisiran Sodium

Lepodisiran is Eli Lilly's investigational GalNAc-conjugated siRNA that switches off liver production of apolipoprotein(a), the protein that assembles into lipoprotein(a) (Lp(a)), a genetically driven cardiovascular risk factor with no approved therapy. Phase 3 ACCLAIM-Lp(a) is testing whether durable Lp(a) lowering translates into fewer cardiovascular events across roughly 12,500 to 14,200 high-risk adults, with a MACE-4 primary endpoint (a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization) [1]. The competitive picture changed sharply on September 4, 2026: Novartis/Ionis's pelacarsen missed its primary endpoint in the Lp(a)HORIZON Phase 3 trial (>8,300 patients), the first cardiovascular outcomes readout for any Lp(a)-lowering drug [8]. That result is class-negative in the sense that antisense-mediated Lp(a) knockdown did not translate to event reduction, and it puts a heavy burden of proof on the two remaining programs, Amgen's olpasiran (siRNA, OCEAN(a)-Outcomes expected 2026 to 2027) and lepodisiran (siRNA, expected 2029 to 2030). If the mechanistically closer siRNA class works, approval opens a multi-billion-dollar residual cardiovascular risk category with no incumbent. If olpasiran also misses, lepodisiran's rationale collapses.

Novel compound, never approved anywhere. Phase 3 ACCLAIM-Lp(a) (NCT06292013) is active with subcutaneous lepodisiran versus placebo [1]. The trial selected the 400 mg subcutaneous dose based on Phase 2 pharmacodynamic data showing approximately 94% Lp(a) reduction from day 60 through day 180 [2]. The main cohort targets roughly 12,500 participants, with an approximate 1,700-participant addendum exploring an alternative dosing schema; earlier registration language referenced enrollment up to 17,300. Expected dosing interval in a commercial label is annual to semiannual, based on the 400 mg dose's durability. No breakthrough therapy, fast track, or orphan designation appears on the public record for lepodisiran itself, though FDA has engaged the Lp(a) space broadly through the pelacarsen and olpasiran programs. Timing is the biggest strategic factor. The trial is event-driven, meaning it does not stop on a calendar but on hitting a target number of cardiovascular events. Lepodisiran started later than pelacarsen and olpasiran and, given the pelacarsen readout in September 2026, will read out third in class, likely 2029 or later depending on event accrual. That has consequences: Lilly's commercial case now rests on either differentiated potency, dosing convenience, or a second-mover safety and efficacy cushion earned by watching the class play out first, and the class starts one point down.

Lp(a) is a lipoprotein particle that bolts apolipoprotein(a) onto an LDL-like core. Blood levels are almost entirely inherited, and roughly 20% of adults carry levels linked to elevated risk of heart attack, stroke, and aortic valve calcification [3]. Statins do nothing to it, PCSK9 inhibitors barely dent it, and diet and exercise are irrelevant. It is a residual cardiovascular risk factor that current medicine has no answer for. The genetic case is unusually strong: Mendelian randomization studies, which use naturally inherited genetic variation as a proxy for lifelong drug effect, show that people born with lower LPA gene activity have less cardiovascular disease across their lifetimes [4]. Lepodisiran uses small interfering RNA (siRNA), a short piece of engineered RNA that instructs cells to shred the messenger RNA for the LPA gene before it can be translated into protein. The drug is conjugated to N-acetylgalactosamine (GalNAc), a sugar tag that hepatocytes grab through a surface receptor called ASGPR, so nearly all of the payload ends up in liver where Lp(a) is assembled. Mechanistically, this differs from pelacarsen (an antisense oligonucleotide using RNase H-mediated mRNA cleavage) in that siRNA drives deeper and longer knockdown. Whether that potency difference matters for events is now the central open question, because pelacarsen achieved substantial Lp(a) lowering (approximately 80%) in Lp(a)HORIZON but still failed on MACE [8]. Genetics validate the target and Phase 2 data confirm lepodisiran hits the biomarker harder and more durably than any competitor [2]. What is unresolved is whether hitting the biomarker prevents events at all.

ACCLAIM-Lp(a) (NCT06292013) is a randomized, double-blind, placebo-controlled event-driven Phase 3 in adults with elevated Lp(a) who either have established atherosclerotic cardiovascular disease or are at high risk for a first cardiovascular event [1]. It is notably the first Phase 3 Lp(a) outcomes trial to include a primary-prevention population alongside secondary-prevention patients, which broadens the potential label but also dilutes event rate. Enrollment targets approximately 12,500 in the main cohort plus a roughly 1,700-participant dosing-schema addendum. Primary endpoint is time to first MACE-4 event: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization. The comparator is placebo on top of guideline-directed background therapy, which almost certainly includes statins and often ezetimibe or PCSK9 inhibitors. The design is orthodox for cardiovascular outcome trials and modeled directly on the pelacarsen Lp(a)HORIZON and olpasiran OCEAN(a)-Outcomes studies, which lets regulators and cardiologists compare across programs on the same endpoint [8][9]. Powering an event-driven trial at this size usually implies the sponsor is targeting roughly a 15% to 20% relative risk reduction in MACE. Given the depth of Lp(a) suppression at the 400 mg dose, that target is not unreasonable, but the main design vulnerability is duration. Even with 5 years of follow-up, whether pharmacological Lp(a) lowering initiated in middle age produces enough absolute event reduction to hit the endpoint remains open, because Mendelian genetics reflect lifetime exposure, not late-in-life intervention. The pelacarsen miss suggests that concern is not academic.

Our model estimates a 49% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase, more secondary endpoints than usual, and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is no longer hypothetical. Pelacarsen's Lp(a)HORIZON miss (September 2026, >8,300 patients) is the first empirical answer to the question of whether pharmacological Lp(a) lowering reduces cardiovascular events, and the answer for that drug was no [8]. The bull case for lepodisiran hinges on two arguments: (1) siRNA delivers deeper and longer knockdown than pelacarsen's ASO, and biomarker exposure below some threshold matters for events, or (2) ACCLAIM-Lp(a)'s inclusion of primary-prevention patients captures earlier-in-disease-course intervention where lifetime-exposure genetics would predict benefit. Both are plausible. Neither is proven, and the class parallel to the CETP inhibitor saga is uncomfortably close: CETP drugs raised HDL beautifully but, with the partial exception of anacetrapib's modest signal in REVEAL, produced almost no MACE benefit [6]. Safety risk is comparatively modest. GalNAc-siRNAs have accumulated a decent safety database through inclisiran, givosiran, and lumasiran approvals, with liver enzyme elevations and injection-site reactions the main issues and no class-defining serious toxicity [7]. That said, ultra-durable near-complete knockdown of a serum protein over decades is a newer regime, and long-term consequences of near-zero Lp(a) in humans are not fully characterized. Commercial risk is now more concentrated. Reimbursement for preventive cardiovascular drugs is uphill even with clean outcome data: PCSK9 inhibitors were priced high, restricted heavily, and took years to reach broad access despite crisp FOURIER and ODYSSEY results. Lilly will compete with Amgen's olpasiran (if it survives OCEAN(a)-Outcomes), Silence Therapeutics's zerlasiran (also siRNA), and, importantly, Lilly's own oral muvalaplin (see biocosm_assessment). Pelacarsen's failure likely narrows rather than widens the payer opening: payers will demand hard MACE data before granting broad access to any Lp(a)-lowering therapy.

The single external event that dominated lepodisiran's near-term risk profile has already occurred: pelacarsen missed Lp(a)HORIZON on September 4, 2026 [8]. The class is now on notice. What remains to watch, in order of importance: (1) The olpasiran OCEAN(a)-Outcomes readout (NCT05581303), expected late 2026 to 2027, is the next binary event and is closer mechanistically to lepodisiran (both are GalNAc-siRNAs). A positive olpasiran result rehabilitates the siRNA subclass and materially lifts lepodisiran's outlook. A miss makes the class-failure interpretation almost impossible to argue against and likely triggers program termination or de-prioritization. (2) Lilly's internal portfolio decision between lepodisiran and muvalaplin. Muvalaplin is Lilly's own oral small molecule that disrupts apo(a)-kringle IV interactions to prevent Lp(a) particle assembly, a mechanism entirely distinct from siRNA knockdown of LPA mRNA. Lilly is running two mechanistically independent Lp(a) programs at the same time, which is unusual and signals hedging: if the siRNA class fails on efficacy, muvalaplin's oral convenience and different mechanism preserves optionality. Watch Lilly's pipeline slides for prioritization signals; a shift of investment toward muvalaplin after any additional class-negative readout would be meaningful. (3) Lilly's cardiovascular commercial base gives it patience: FY2025 revenue was $65.2 billion, of which Mounjaro and Zepbound alone accounted for 56%, per Lilly's 10-K [10]. Lilly does not need lepodisiran to work to protect the enterprise, which reduces the pressure to force a positive spin on marginal readouts. (4) Addressable market context: roughly 20% of adults globally carry elevated Lp(a) (>50 mg/dL), a large addressable pool [3], but PCSK9 precedent suggests real-world access will be restricted to secondary-prevention and high-risk populations at launch. (5) Composition-of-matter exclusivity for lepodisiran should extend into the late 2030s or beyond given typical patent filing timelines for a compound that entered clinical development in the early 2020s, so the commercial window if it works is long. Realistic recheck cadence: revisit immediately after any OCEAN(a)-Outcomes disclosure from Amgen, and again at Lilly's next major R&D day for muvalaplin-versus-lepodisiran prioritization signals. Until then, lepodisiran's value is almost entirely contingent on external data, and the trend of that data is unfavorable.